Literature DB >> 8851568

Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.

L E Bermudez1, C B Inderlied, P Kolonoski, M Wu, L Barbara-Burnham, L S Young.   

Abstract

Levofloxacin, ofloxacin, and Bay Y 3118 are new fluoroquinolones with variable in vitro bacteriostatic and bactericidal activities against the Mycobacterium avium complex (MAC). The potential therapeutic activities of these agents both alone and combined with ethambutol were evaluated in a human macrophage test system and in the beige mouse animal test system with MAC strain 101. Bay Y 3118 at a human-equivalent dose of 30 mg/kg/day for 4 weeks caused a significant reduction in mortality compared with that in untreated controls (P = 0.02). Bay Y 3118 also caused significant reductions in the number of MAC organisms in the blood, liver tissue, and spleen tissue compared with those in untreated controls. Levofloxacin at a human-equivalent dose of 200 mg/kg/day was associated with a significant reduction in mortality (10 versus 39%); however, treatment with either levofloxacin or ofloxacin (200 mg/kg/day) did not result in significant reductions in the numbers of MAC organisms in blood, liver, and spleen compared with those in untreated controls. When Bay Y 3118 was combined with ethambutol, there was no enhancement in therapeutic activity except in the spleen in terms of CFU per gram (reductions of 89% compared with the untreated control, 63% compared with Bay Y 3118 alone, and 72.5% compared with ethambutol alone). Levofloxacin in combination with ethambutol was more active than either drug alone in the reduction of organisms in blood, liver, and spleen. Bay Y 3118 was the most active fluoroquinolone for monotherapy of MAC infection in beige mice, and the combination of ethambutol plus either levofloxacin or ofloxacin was at least additive. In summary, this study demonstrates that quinolones, although active, are inhibitory against MAC in vivo and that there is little correlation between the activity of quinolones in vitro and the activity in mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851568      PMCID: PMC163155     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.

Authors:  G P Bongaerts; J A Hoogkamp-Korstanje
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

2.  Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells.

Authors:  T Nichterlein; M Kretschmar; C Budeanu; J Bauer; W Linss; H Hof
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

3.  Noncytotoxic combinations of topical antimicrobial agents for use with cultured skin substitutes.

Authors:  S T Boyce; G D Warden; I A Holder
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

4.  Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes.

Authors:  I García; A Pascual; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

5.  The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS.

Authors:  C A Kemper; D Havlir; D Haghighat; M Dubé; A E Bartok; J P Sison; Y Yao; B Yangco; J M Leedom; J G Tilles
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226

6.  Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.

Authors:  C B Inderlied; L Barbara-Burnham; M Wu; L S Young; L E Bermudez
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

7.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

8.  Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis.

Authors:  P S Skinner; S K Furney; D A Kleinert; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

9.  Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages.

Authors:  N Mor; J Vanderkolk; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

10.  Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus.

Authors:  G W Kaatz; S M Seo; C A Ruble
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  11 in total

1.  Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice.

Authors:  L E Bermudez; K Nash; M Petrofsky; L S Young; C B Inderlied
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of Mycobacterium avium subsp. paratuberculosis.

Authors:  S L Williams; N B Harris; R G Barletta
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

3.  Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials.

Authors:  E C Miltner; L E Bermudez
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

4.  Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.

Authors:  L E Bermudez; P Kolonoski; M Wu; P A Aralar; C B Inderlied; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Wu; P Aralar; L S Young
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

6.  Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Petrofsky; P Aralar; M Wu; L S Young
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.

Authors:  Luiz E Bermudez; Nima Motamedi; Christopher Chee; Gyulnar Baimukanova; Peter Kolonoski; Clark Inderlied; Priscilla Aralar; Guoqiang Wang; Ly Tam Phan; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

8.  Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.

Authors:  N Rastogi; K S Goh; A Bryskier; A Devallois
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

9.  Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.

Authors:  L E Bermudez; P Kolonoski; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.

Authors:  Yoshihisa Kohno; Hideaki Ohno; Yoshitsugu Miyazaki; Yasuhito Higashiyama; Katsunori Yanagihara; Yoichi Hirakata; Kiyoyasu Fukushima; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.